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Abstract
Background: AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use,
either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not
been identified.
Methods/Design: An open-label, 2-arm, non-inferiority, multi-centre randomised controlled trial is being
conducted to determine the optimal single-dose treatment with AmBisome®.
Patients in the single-dose arm will receive one infusion on day 1, at a dose depending on body weight. For the
first group of patients entered to the trial, the dose will be 7.5 mg/kg, but if this dose is found to be ineffective
then in subsequent patient series the dose will be escalated progressively to 10, 12.5 and 15 mg/kg. Patients in the
reference arm will receive a multi-dose regimen of AmBisome® (3 mg/kg/day on days 1-5, 14 and 21: total dose
21 mg/kg). Patients will be hospitalised for approximately one month after the start of treatment and then
followed up at three and six months. The primary endpoint is the status of patients six months after treatment. A
secondary endpoint is assessment at day 30. Treatment success is determined as the absence of parasites on
microscopy samples taken from bone marrow, lymph node or splenic aspirates. Interim analyses to assess the
comparative efficacy of the single dose are planned after recruitment of 20 and 40 patients per arm. The final non-
inferiority analysis will include 120 patients per arm, to determine if the single-dose efficacy 6 months after
treatment is not more than 10% inferior to the multi-dose.
Discussion: An effective, safe single-dose treatment would reduce hospitalization and treatment costs. Results will
inform the design of combination treatment studies.
Trial Registration: ClinicalTrials.gov NCT00832208
Background
Visceral Leishmaniasis (VL) is a parasitic disease that is
transmitted by phlebotomine sandflies, and is fatal if not
treated. Estimates suggest there are 500,000 cases per
year, with 90% of cases occurring in India, Bangladesh,
Nepal, Sudan, Kenya, Ethiopia and Brazil [1,2]. In East
Africa, the disease has been known to occur in cyclical
epidemics, one of which resulted in over 100,000 deaths
in Southern Sudan between 1984-94 [3,4]. Parasitologi-
cal diagnosis is determined by lymph node, bone mar-
row and spleen aspirates. The mainstay of control in
East Africa, where the disease is believed to be largely
anthroponotic, has been case finding and treatment.
Treatment options for VL in the region has been limited
to antimonials (sodium stibogluconate or glucantime),
given intramuscularly (IM) or intravenously (IV) for 28-
30 days. This long and relatively toxic treatment is
inconvenient for patient management. Two other treat-
ments; paromomycin, a 3- week IM treatment, and
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miltefosine, a 4-week oral treatment, have recently been
developed and registered for VL in India. Both are in
development in Africa, but both require relatively long
courses, have some toxicity and there are contraindica-
tions and issues with compliance [2].
AmBisome®, a liposomal formulation of Amphotericin
B has been shown to be safe and effective against leishma-
niasis. In trials in India, an efficacy of 90% was obtained
with a single dose of 5 mg/kg [5,6]. A major limitation of
this treatment has been its cost but recently, the drug has
been offered at a preferential price for the treatment of VL
by its producer, Gilead. This has raised considerable inter-
est in its use either as a single dose treatment or as part of
a combination treatment where a single dose of AmBi-
some® might be followed by a short course of a compa-
nion drug such as miltefosine[7]. There are limited data
on the use of AmBisome® in East Africa. One small phase
II trial in Kenya showed an efficacy of 20% at a total dose
of 6 mg/kg, 90% at a total dose of 10 mg/kg and 100% at a
total dose of 14 mg/kg [8].
At the time of developing this study protocol, there
was a recommendation made to use AmBisome® in East
Africa at a total dose of 21 mg/kg [9] but this recom-
mendation was based on experience with the drug in
India and it is not known if this is the appropriate dose
for use in the treatment of African patients. That there
might be geographical difference in drug efficacy is illu-
strated by a recent study conducted by the authors, as
members of the Leishmaniasis East Africa Platform
(LEAP), and Drugs for Neglected Diseases initiative
(DNDi), which showed that the efficacy of paromomycin
for VL, is lower in East Africa, than in India[10]. There
is a clear need 1) to demonstrate the efficacy of AmBi-
some® given under the standard recommended multiple
dose regimen; and 2) to determine if lower single doses
of AmBisome® could be used to treat VL.
Methods/Design
Study Design
An open-label, non-inferiority, multi-centre, individually
randomised controlled trial.
Main Hypothesis
The hypothesis is that a sufficiently large single dose of
AmBisome® is safe and is not inferior in efficacy to a
multiple dose regimen of AmBisome®.
Main Objective
To determine the minimum single-dose treatment regi-
men of AmBisome® that is efficacious and safe.
Setting
Trial sites are in three locations, each in endemic areas
for VL. These are Gondar University Hospital in
Amhara State - Ethiopia; Arba Minch Hospital, South-
ern Nations, Nationalities and Peoples State - Ethiopia;
and Kassab Hospital, Gedarif State, Sudan. All data col-
lected in the trial are analysed in the data centre located
at the Coordination Centre for the trial at the Kenya
Medical Research Institute (KEMRI) in Nairobi, Kenya.
Outcome measures
Primary outcome
Definitive Cure - defined as absence of parasites 6
months after the end of the 30 hospitalisation period
following the initiation of treatment (i.e., 7 months after
the start of treatment), confirmed by splenic or bone
marrow aspiration.
Secondary outcomes
Initial Cure - defined as parasitological clearance, mea-
sured on day 30 after initiation of treatment on day 1,
confirmed by lymph node, splenic or bone marrow
aspiration.
Sample Size
The final analysis will be based on the primary efficacy
endpoint of definitive cure. Assuming a true efficacy of
95% in both arms, 120 patients per arm will provide
80% power to detect if the efficacy of the single-dose
treatment regimen is no more than 10% inferior to the
reference multi-dose regimen [11].
The trial design allows for a dose escalation in the sin-
gle-dose arm at the pre- specified interim analysis time
points if the single-dose regimen is found to be performing
poorly, compared to the multi-dose and based on a test of
difference in the proportion of patients achieving initial
cure, measured at the secondary efficacy endpoint on day
30 (Figure 1). Based on a two-sided significance test for a
difference in proportions at the 5% level assuming 95%
efficacy in the reference arm, 20 patients per arm will pro-
vide approximately 80% power to detect a difference if the
test arm is less than 60% effective and 40 patients per arm
will provide 80% power to detect a difference in efficacy if
the test arm is less than 70% effective [12].
Choice of NI margin
A margin of 10% below an assumed efficacy of 95% was
considered acceptable based on clinical acceptability
given the limited availability of possible treatments for
VL and sample size considerations based not only on
power but on recruitment time projections.
Allocation
Patients will be randomised to one of two treatment
arms; either the reference multi- dose regimen or the
test single-dose regimen.
Block randomisation by site will be used to minimise
imbalance in multi-centre interim analyses. The user-
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written program ralloc for Stata will be used to obtain
the final sequence[13]. The process of randomisation
generation and the resulting final randomisation list,
produced by the trial statistician will be kept securely at
the DNDi Data Centre. Sequentially numbered, sealed,
opaque envelopes will conceal random allocation to
treatment until immediately prior to receipt of first
treatment administration.
Blinding of the patients or clinicians was not consid-
ered feasible or ethical; placebo injections in the single-




A total dose of 21 mg/kg given as a 3 mg/kg intra-vas-
cular (IV) infusion on days 1,2,3,4,5,14 and 21, was cho-
sen as the reference treatment regimen, expected to
achieve efficacy of 95% [9,14].
Single-dose regimen(s)
The trial will compare only one single-dose test regimen
to the multi-dose regimen during any one recruitment
period but the trial design does allow for testing of
incrementally higher single-doses in later recruitment
periods if lower doses are ineffective (see above and
Type of Analysis section).
Based on experience from treatment trials for VL in
India and Kenya[15], either 7.5 mg/kg or 10 mg/kg is
likely to be the lowest dose to show suitable efficacy in
a single-dose regimen [14-16] although the efficacy of
treatment regimens used in India can be substantially
lower in African setting [8,10]. The trial will begin with
a 7.5 mg/kg single-dose regimen in the test arm. If this
regimen is found to be ineffective according to pre-spe-
cified criteria at the time of an interim analysis, the trial
design allows for recruitment and randomisation into
the two arms to continue with a higher single-dose (see
Type of Analysis section). Higher single doses to be
used, if 7.5 mg/kg is ineffective, are 10 mg/kg,12.5 mg/
kg and 15 mg/kg. It is considered that 15 mg is the




Aged 4 years or older; VL proven by parasitological exami-
nation of splenic aspirate, lymph node or bone marrow




Day 30 Assessment: Secondary Endpoint
Interim analyses after 20 and 40 patients per arm
Multi-dose arm 1
Six months post day 30 assessment: Primary Endpoint
Final non-inferiority analysis with 120 patients per arm
Figure 1 Trial Flow CONSORT Diagram. 1 dosage: 3 mg/kg on days 1-5, 7 and 14 (total dose 21 mg/kg). 2 possible single-doses of 7.5, 10, 12.5
& 15 mg/kg on day 1.
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weeks; written informed consent to participate (for chil-
dren, by parent or guardian); HIV negative status.
Exclusion criteria
’In extremis’ signs/symptoms of severe VL; receipt of
anti-leishmanial treatment or investigational (unli-
censed) drugs within previous 6 months; known under-
lying chronic disease, such as severe cardiac, pulmonary,
renal, or hepatic impairment; renal function tests
(serum creatinine) outside the normal range; liver func-
tion tests more than 3 times the normal range; platelet
count less than 40,000/mm3; known alcohol abuse; preg-
nancy or lactation; concomitant acute drug usage for
malaria and bacterial infection, pneumonia within pre-
vious 7 days; known hypersensitivity to AmBisome® or
amphotericin B.
In addition, patients presenting with severe dehydra-
tion should be re-hydrated before consideration for trial
entry and those presenting with acute bacterial co-infec-
tion e.g. malaria, pneumonia must have these infections
treated prior to trial entry. In the Sudanese site, recruit-
ment until the end of the first interim analysis period
will include those aged 12 years and above before
widening to age 4 years and above, at the request of the
Sudanese Ethics Committee.
HIV-status and VCT
All patients (or parents/guardians) will be offered
Voluntary Counselling & Testing (VCT) for HIV screen-
ing/testing in accordance with national guidelines. This
trial specifically requires HIV negative patients, therefore
patients who refuse counselling and testing, or who test
positive will be excluded from the trial, but will be trea-
ted for VL according to national guidelines and if HIV
positive referred to national HIV treatment programs
for assessment and treatment with anti-retrovirals
(ARVs) if indicated.
Consent
Standardised consent forms, adapted to the local con-
text, translated into local languages and approved by
ethics committees are to be used. Signatures or thumb-
prints will be obtained for consent, with witnesses in the
case of illiterate subjects. Parents or guardians will be
asked to provide consent for all children and in Ethio-
pia, depending on their age and level of comprehension,
children will be asked to give their assent, as required
by local regulations.
Patients who do not meet inclusion criteria or who do
not give consent will be treated outside the trial, accord-
ing to national treatment guidelines.
Type of analysis
The final analysis will be based on a comparison of defini-
tive cure of the single-dose treatment regimen to the
reference treatment regimen. If the treatments in the two
arms are equally efficacious, the trial is powered such that
the confidence interval around the difference in efficacies
of the two regimens will be no more than 10% (non infer-
iority margin Δ = 0.1). The primary analysis will be by
intention to treat (ITT). A per-protocol (PP) analysis will
exclude patients deemed to have major protocol deviations
but include minor deviations, where major and minor
deviations are pre-specified prior to recruitment.
Two interim analyses are planned after recruitment of
a pre-specified number of patients per arm, to allow for
rapid elimination of inadequate dosage regimens. The
interim analysis will be assessed at the secondary end-
point, initial cure, measured on day 30, where treatment
is initiated on day 1 (Figure 1).
The first single-dose regimen tested will be 7.5 mg/kg
body weight. Interim analyses are planned after recruit-
ment of 20 and 40 patients per arm. Randomisation will
pause once the desired number of patients for each
interim analysis has been recruited, in order to carry out
the interim analysis and assess if the trial will continue
with the current single-dose or a higher single-dose. If
interim results indicate a Fisher’s test of a difference
with a p-value ≤ 0.05, randomisation will re-start with
the next highest dose in the single-dose regimen arm.
Interim analyses will take place as pre-specified for each
dosage tested in the single-dose treatment arm.
Schedule of Assessments and Expected Side Effects
During the month that patients are hospitalised, formal
weekly assessment will take place to monitor vital signs
and other clinical characteristics (Table 1). During these
weekly assessments and during follow up, safety will be
assessed by means of haematological, urinalysis and bio-
chemical monitoring (Table 1). Known side effects
include infusion related fever and shivers [6,17]. Vital
signs will be measured during infusions and patients
will be asked if they experience discomfort during the
infusion. In addition, patients will be asked daily during
treatment and at each visit during follow up if they have
suffered any side-effects or adverse events (AE). Electro-
cardiograms (ECG) will be performed where clinically
indicated by patient’s signs or symptoms. Site investiga-
tors will use their judgment to determine the degree of
certainty with which each adverse event is attributed to
drug treatment. Causality will be classified as; not
related, unlikely, suspected (reasonable possibility) or
probable. The assessment and classification of intensity/
severity and causality in relation to VL and the study
treatment will be based on the investigator’s clinical
judgment and pre-specified criteria according to com-
mon terminology criteria (CTC) [18] and applicable in
the study population. Serious adverse events (SAE) will
be recorded as such if the event is fatal or considered
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life threatening, disabling or incapacitating or results in
re/hospitalisation, prolonged hospital stay or is asso-
ciated with congenital abnormality, cancer or overdose
(either accidental or intentional), in addition to any
experience suggestive of a significant hazard, contra-
indication, side effect or precaution that might be asso-
ciated with the use of the drug. All SAEs will be
reported to and reviewed by the Medical Coordinator
within 24 hours and reported to the Data and Safety
Monitoring Board (DSMB) within 7 days. Patients with
SAEs or AEs will be followed-up until the condition
resolves or stabilises.
Rescue medication
In the event of failure to respond to treatment, clinical
deterioration or relapse at any time during the study,
rescue treatment will be given for patients in the single-
dose arm as a full course of AmBisome®. In the multi-
dose arm and in the single-dose arm for patients with-
drawn from treatment due to an adverse reaction,
patients will be treated with sodium stibogluconate
(SSG) at 20 mg/kg/day for 30 days by intramuscular
injection, and intravenously if indicated.
Concomitant Medication
Details of all concomitant medication taken during the
study will be recorded in the case report form (CRF) with
indication, daily dose, route and dates of administration.
Dissemination of Results
An interim analysis report presenting the efficacy (95%
confidence intervals) in each arm and the p-value from
a Fisher’s test of a difference will be provided to the
DSMB. This report will also contain a listing of serious
adverse events. The DSMB will review the results and
report back to the coordination group, to confirm if the
stopping rule for a single-dose has been met. Adverse
event listings are to be provided at the request of the
DSMB. The DSMB, through the Chair may request
additional efficacy and safety data if they have concerns
relating to trial conduct or other ethical and safety
issues [19]. At the end of the trial, the analysis report
will be circulated to Principal Investigators, DSMB,
Ethics Committees, Ministries of Health and Drug Regu-
latory Authorities.
Ethical Approval
Ethics approval has been obtained from national and
local Ethics Committees in Sudan and Ethiopia prior to
the start of the trial in each country, where required
and also from the London School of Hygiene & Tropical
Medicine Ethics Committee.
Ancillary studies
Complementary sub-studies are feasible within this large
collaborative project and appropriate ethical approval
will be sought as necessary.
Table 1 Data Collection and Assessment Schedule
Assessments In-patient assessment (day) Follow-up (months)
BL 1 2,3,4,5 7 14 21 30 3 6
Clinical assessment (BP, body temperature, weight, height1, spleen size) X X X X X X X
Haematology
(HB, WBC, Platelet)
X X X X X X X
Biochemistry2 (Urea, creatinine, ALT, AST, Na+, K+, Mg2+) X X X X X X X X
CARPA X X X X
Pharmacodynamic Assessment X X X X X X X
Urinalysis (blood, protein, glucose) X X X X X X
Parasitology (splenic, LN, BM aspirates)3 X X X X
HIV test X
Electrocardiogram Examination4 X X X X X X
Pregnancy test X
Dosing - including monitoring of vital signs5 X X X X
Adverse events6 X X X X X X X X X
BL = Baseline, BP = blood pressure, HB = Haemoglobin, WBC = white blood cell count, AST = aspartate aminotransferase, ALT = Alanine transaminase, Na+=
Sodium, K+ = Potassium, Mg2+ = Magnesium, CARPA = complement activation related pseudo allergy products, LN = lymph node, BM = bone marrow, HIV =
Human immunodeficiency virus.
1 Body height measurements on Day 0 only.
2 Day 3 only.
3 Parasitological investigations to be undertaken in the event of clinically significant abnormalities at 3 months follow-up.
4 ECG if clinically indicated.
5 Single-dose arm monitoring on day 1 only.
6 Treatment emergent adverse events have onset at anytime between day 1 and day 60 for each patient.
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Organisation
The DNDi Coordination Team, based mainly at the Coor-
dination Centre, DNDi Africa, Kenya Medical Research
Institute, Nairobi are responsible for collation and submis-
sion of protocol amendments, organisation of training for
trial staff, monitoring and supervision of trial conduct, day
to day management of the trial, harvesting data collected
at each site, trial monitoring visits and data management,
all to Good Clinical Practice (GCP) standards.
Training
All trial site staff; physicians, nurses, laboratory technicians
and pharmacists will receive training on the study proto-
col, study specific procedures and International Confer-
ence on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use - Good
Clinical Practice (ICH-GCP) guidelines [20,21]. Additional
training sessions will be provided as required, using exter-
nal consultants where necessary. Documentation of receipt
of training is maintained at the coordination centre.
Quality control and quality assurance
Suitably qualified Clinical Monitors trained in GCP will
regularly visit trial sites to monitor all aspects of the
trial including; informed consent procedures, drug
accountability, source data verification, adverse event
reporting, sample handling, analysis and storage and
secure data storage.
Data collection and data management
Data are to be recorded on 3-part No Carbon Required
(NCR) CRFs by site investigators, transcribed from hospi-
tal source data. Unique patient identifiers, assigned at the
time of randomisation, are linked to unique hospital
record numbers. During monitoring visits, CRF data will
be cross-checked against hospital source data by clinical
monitors. The top sheet for each page of the CRF pages
is to be brought to the central Data Centre for double-
entry into GCP compliant open-access database software
OpenClinica, version 2.7 [22]. Following validation, data
will be read into Stata, version 11 special edition [23] and
pre-programmed command files will be used to generate
lists of data value queries in a thorough data cross-check-
ing process. Query forms are to be automatically gener-
ated via Microsoft Access© database software and
emailed to trial sites, copied to clinical monitors. The
sites will print and make resolutions. At the next moni-
toring visit, monitors will verify resolutions and deliver to
the Data Centre. Data corrections will be programmed in
Stata to complete the data cleaning audit trail.
Publication policy
DNDi, as sponsor, will render all necessary assistance to
investigators to ensure publication of results in an
international peer-reviewed journal in a timely manner,
for the benefit of patients and to inform decision-mak-
ing with respect to national treatment guidelines for VL.
All investigators will be acknowledged when reporting
the primary results of the trial through a group author-
ship. Ancillary studies will acknowledge those involved
by name where appropriate.
Confidentiality
Trial site records will contain names and residential
information for each patient to allow follow-up to take
place. Only the unique numeric identifier assigned to
patients will be extracted from patient records trans-
ferred to the central Data Centre. Patient data will be
kept securely at trial sites under the responsibility of the
site investigator.
Audit
During the course of the trial, site audits will be under-
taken to assess compliance to ICH GCP guidelines. Spe-
cific issues to be assessed include adherence to the
protocol and standard operating procedures (SOP), con-
sent, laboratory practise, documentation and record
keeping. All areas of non-compliance will be addressed
by the trial coordination centre.
Termination of the study
On approaching the end of planned recruitment, the
trial coordination office will send written instructions by
email to each site to advise on the date to cease recruit-
ment. All patients will be followed up as per the proto-
col, data collected and cleaned. Once the data lock has
been completed, site close out visits will be performed
by the coordination team and clinical monitors. A deci-
sion for premature termination will be taken in consul-
tation and agreement with the sponsor, investigators
and DSMB. All relevant ethics committees and regula-
tory authorities will also be informed of the reason for
termination. Trial master files and CRFs will be archived
by the coordination centre in Nairobi for 15 years.
Indemnity
DNDi as sponsor holds clinical trial insurance to indem-
nify the study participants for any injury or harm, which
occurs during the performance of the trial.
Discussion
Given the pressing need to develop new treatments for
VL in East Africa, this trial aims to meet both phase II
and III development objectives by identifying an effec-
tive dosage and demonstrating non-inferiority in a suita-
bly powered study. Hence, this trial will allow the
evaluation of an effective single-dose regimen and to
inform a strategy on use of AmBisome® in the region.
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The use of a combined phase II and III approach will
also allow a cost effective approach considering the hur-
dles faced in conducting and running a clinical trial in
very remote, resource limited settings of VL endemicity.
The conduct of the trial through a multi country
research platform (LEAP) will also facilitate its imple-
mentation, minimise duplication of efforts and allow
regional capacity building. The expected outcome will
be the identification of an efficacious single dose that
can also be used as part of a combination treatment.
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